ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
12 déc. 2023 07h00 HE
|
ADMA Biologics, Inc.
Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval Expanded Label in the U.S. Now Includes Pediatric PI Patients 2 Years of Age and...
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
16 nov. 2023 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla. and LAUREL, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company...
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
08 nov. 2023 16h05 HE
|
ADMA Biologics, Inc.
3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash...
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
01 nov. 2023 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
09 août 2023 16h05 HE
|
ADMA Biologics, Inc.
2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement ...
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
02 août 2023 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
19 juil. 2023 07h00 HE
|
ADMA Biologics, Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 ...
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
10 mai 2023 16h05 HE
|
ADMA Biologics, Inc.
1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1), Totaling $2.5 Million,...
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
03 mai 2023 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Amendment to Credit Agreement
02 mai 2023 07h00 HE
|
ADMA Biologics, Inc.
Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA...